Described herein are methods for quantifying IAIP levels in a sample.

The present invention is directed towards methods, compositions and kits for testing SARS-CO-V2 virus in a sample. The methods determine the presence of a viral 3CL protease by contacting the sample with a peptide compound capable of being cleaved by the protease to form peptide compound fragments. Detection of a peptide compound fragment confirms the presence of the virus.

A method for predicting sepsis or diagnosing systemic inflammatory response syndrome (SIRS) and/or sepsis in a subject comprises determining levels of at least three markers selected from CCL23, A1AT, CRP, sICAM, PLA2, IL-6, procalcitonin, MMP8, TNFalpha, AcPGP, enzymatic MMP activity, TIMP1, sRAGE and desmosine in a sample taken from the subject. The combined levels of the at least three markers are used to predict or diagnose SIRS and/or sepsis. The methods may be performed on a subject with SIRS and which is used to identify an infection in the subject. A preferred panel of markers includes CCL23, A1AT, sICAM, sICAM/VCAM-1 and CRP. Corresponding products, methods of treatment and medical uses are provided.

The preparation and use of systems to provide surrogate whole blood controls using coagulation modifiers to simulate human whole blood in coagulation assays are disclosed.

The present invention provides purified protease inhibitors derived from microorganisms alone or in combination with bacteriocins and/or antibodies. The protease inhibitors may also be expressed by microbiome or probiotic microorganisms alone or in combination with bacteriocins and/or antibodies. The invention also provides methods and compositions for improving the expression of endogenous or heterologous protease inhibitors alone or in combination with bacteriocins and/or antibodies. The invention is useful for treating a variety of inflammatory disorders including acne, psoriasis, eczema, atopic dermatitis and inflammatory bowel disease.

In the present invention, a method and assay for the detection of proteases and protease inhibitors using colloidal gold nanoparticles and peptide substrates, which are selectively recognized and cleaved by proteases being assayed, is disclosed. In this assay, the mechanism of signal generation relies on peptide sequence induced aggregation of gold nanoparticles, which are used as signal reporters. The peptide sequences that induce aggregation are either the intact peptide substrates or proteolytic fragments of the intact peptide substrate wherein the proteolytic fragments are produced by the protease being assayed. The present invention provides a novel, simple, sensitive, and inexpensive colloidal gold nanoparticle-based colorimetric assay that allows both visual and quantitative detection of proteases and protease inhibitors.

The present invention relates to a method for detecting specific proteins in amniotic fluid to predict the risk of preterm birth. The method determines different protein markers in premature amniotic fluid samples and normal amniotic fluid samples to predict the risk of preterm birth, and apply the expression levels of these protein markers to build a set of prediction models. This allows the medical staff to be prepared and greatly reduces the threat to the fetus.

An adenocarcinoma detection method based on a protein fragment of WFDC2 protein in a sample originating from a subject, the method comprising determining a presence of adenocarcinoma by comparing a first determination value and a threshold value set in advance, the first determination value being a value derived by dividing a first fragment quantity, which is a quantity of a protein fragment having an amino acid sequence of SEQ ID NO: 1 in the sample as determined by an ELISA method, by a reference quantity defined by a total quantity of WFDC2 protein or a creatinine concentration in the sample as determined by an ELISA method.

The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.

The present disclosure relates to an assay that measures the level of factor Xa inhibitors in a sample by detecting residual factor Xa activity. In particular, the assay utilizes a mutant variant of prothrombin that lacks proteolytic activity; a prothrombinase complex mixture; and a thrombin-specific inhibitor and measures the factor Xa activity.